Lídia Fonseca - Academia.edu (original) (raw)

Papers by Lídia Fonseca

Research paper thumbnail of Complex Alternative Cytoplasmic Protein Isoforms of the Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 Generated through Noncanonical Translation Initiation

Journal of Virology, 2012

Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) p... more Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) protein is constitutively expressed in all KSHV-infected cells, as well as in all forms of KSHV-associated malignancies. LANA1 is a multifunctional KSHV oncoprotein containing multiple repeat sequences that is important for viral episome maintenance and the regulation of cellular and viral gene expression. We characterize here multiple LANA1 isoforms and show that ∼50% of LANA1 is naturally generated as N-terminally truncated shoulder proteins that are detected on SDS-PAGE as faster-migrating shoulder bands designated LANA1 S . Higher-molecular-weight LANA1 S isoforms initiate downstream at noncanonical sites within the N-terminal region, whereas lower-molecular-weight LANA1 S isoforms initiate downstream within the central repeat 1 domain. LANA1 S proteins lack an N-terminal nuclear localization signal motif, and some isoforms differ from full-length, canonical LANA1 by localizing to per...

Research paper thumbnail of Lentiviral target-specific strategy for molecular therapy

Tese de doutoramento, Farmacia (Microbiologia), Universidade de Lisboa, Faculdade de Farmacia, 2012

Research paper thumbnail of KSHV Latency in Transformed B-cells: The Role of LANA1 as a Therapeutic Target

Virology: Research and Treatment

Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kapo... more Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kaposi as an idiopathic, multiple pigmented sarcoma of the skin. This type of KS, later classifi ed as classic KS, predominantly occurred in elderly people, particularly men of Mediterranean, Eastern European, or Jewish descent. A high occurrence of African or endemic KS was reported during the early 1950's in equatorial African countries, while during the 1960's KS emerged among immune-suppressed patients following organ transplantation. A tremendous increase in the incidence of KS was noticed during the early 1980's in parallel with the acquired immunodefi ciency syndrome (AIDS) epidemic, leading to a formal recognition of KS as an AIDS-associated malignancy. The geographic variations in the incidence of KS together with the relatively high occurrence of AIDS-KS, particularly among homosexual men, suggested the existence of a unique KS infectious agent (7, 8). In 1994 Chang and colleagues, amplifi ed two novel DNA sequences from an AIDS-associated KS lesion, by using a subtractive hybridization technique (representational difference analysis (RDA)). These sequences displayed homology to herpesviral capsid and tegument genes and led to the complete sequencing of the 165 Kbp viral genome of the newly discovered virus, Kaposi's Sarcoma-Associated Herpesvirus (KSHV) or human herpesvirus 8 (HHV-8). KSHV was established as being present in virtually all pathologically confi rmed KS specimens (11, 12). Treatment with highly active antiretroviral therapy (HAART) has been associated with a dramatic decline in the incidence of KS (31), so that AIDS-associated KS is uncommon overall in the Western world. Sub-Saharan Africa has the highest rates of infection (due mostly to the high rates of AIDS) with many countries experiencing sera-prevalence rates exceeding 60%, so that in certain African countries it is now the most common cancer in adult men, and the second most common in adult women (44). The incidence of KS among transplant recipients is proportional to the ethno-geographical prevalence of KSHV, ranging from 0.5% in most Western countries to 5.3% in Saudi Arabia (50). In addition to KS, which is a tumour of endothelial cell origin, several haematological predominantly B cell disorders are also associated with KSHV. The two most well characterized are AIDS-associated primary effusion lymphomas (PEL) and a subset of multicentric Castleman's disease (MCD), an aggressive lymphoproliferative disorder. PELs are monoclonal, non-Hodgkin's B cell lymphomas that are commonly co-infected with EBV. Cell lines established from PEL, unlike KS tumour explants, stably maintain viral episomes at high copy number (30-150 copies per cell) and are the source of virus for most virologic and serologic studies. Most studies on latency of gammaherpesviruses (EBV) used lymphoblastoid cell lines that were derived from lymphomas or were established by in vitro infection/immortalization of peripheral blood lymphocytes. In vitro immortalized cells lines can be cultured indefi nitely. PEL cell lines that carry latent KSHV have been successfully established, although no in vitro immortalization of B lymphocytes has been reported yet (10, 44). KSHV viral genome consists of a ∼140kb long unique coding region fl anked by a multiple GC rich ∼800bp TRs (terminal repeats) giving a total estimated size of around 170kb (57, 60). In analogy

Research paper thumbnail of KSHV Latency in Transformed B-cells: The Role of LANA1 as a Therapeutic Target

Virology: Research and …, 2008

Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kapo... more Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kaposi as an idiopathic, multiple pigmented sarcoma of the skin. This type of KS, later classifi ed as classic KS, predominantly occurred in elderly people, particularly men of Mediterranean, Eastern European, or Jewish descent. A high occurrence of African or endemic KS was reported during the early 1950's in equatorial African countries, while during the 1960's KS emerged among immune-suppressed patients following organ transplantation. A tremendous increase in the incidence of KS was noticed during the early 1980's in parallel with the acquired immunodefi ciency syndrome (AIDS) epidemic, leading to a formal recognition of KS as an AIDS-associated malignancy. The geographic variations in the incidence of KS together with the relatively high occurrence of AIDS-KS, particularly among homosexual men, suggested the existence of a unique KS infectious agent (7, 8). In 1994 Chang and colleagues, amplifi ed two novel DNA sequences from an AIDS-associated KS lesion, by using a subtractive hybridization technique (representational difference analysis (RDA)). These sequences displayed homology to herpesviral capsid and tegument genes and led to the complete sequencing of the 165 Kbp viral genome of the newly discovered virus, Kaposi's Sarcoma-Associated Herpesvirus (KSHV) or human herpesvirus 8 (HHV-8). KSHV was established as being present in virtually all pathologically confi rmed KS specimens (11, 12). Treatment with highly active antiretroviral therapy (HAART) has been associated with a dramatic decline in the incidence of KS (31), so that AIDS-associated KS is uncommon overall in the Western world. Sub-Saharan Africa has the highest rates of infection (due mostly to the high rates of AIDS) with many countries experiencing sera-prevalence rates exceeding 60%, so that in certain African countries it is now the most common cancer in adult men, and the second most common in adult women (44). The incidence of KS among transplant recipients is proportional to the ethno-geographical prevalence of KSHV, ranging from 0.5% in most Western countries to 5.3% in Saudi Arabia (50). In addition to KS, which is a tumour of endothelial cell origin, several haematological predominantly B cell disorders are also associated with KSHV. The two most well characterized are AIDS-associated primary effusion lymphomas (PEL) and a subset of multicentric Castleman's disease (MCD), an aggressive lymphoproliferative disorder. PELs are monoclonal, non-Hodgkin's B cell lymphomas that are commonly co-infected with EBV. Cell lines established from PEL, unlike KS tumour explants, stably maintain viral episomes at high copy number (30-150 copies per cell) and are the source of virus for most virologic and serologic studies. Most studies on latency of gammaherpesviruses (EBV) used lymphoblastoid cell lines that were derived from lymphomas or were established by in vitro infection/immortalization of peripheral blood lymphocytes. In vitro immortalized cells lines can be cultured indefi nitely. PEL cell lines that carry latent KSHV have been successfully established, although no in vitro immortalization of B lymphocytes has been reported yet (10, 44). KSHV viral genome consists of a ∼140kb long unique coding region fl anked by a multiple GC rich ∼800bp TRs (terminal repeats) giving a total estimated size of around 170kb (57, 60). In analogy

Research paper thumbnail of Termination of NF-κB activity through a gammaherpesvirus protein that assembles an EC5S ubiquitin-ligase

The EMBO Journal, 2009

Host colonisation by lymphotropic gammaherpesviruses depends critically on the expansion of viral... more Host colonisation by lymphotropic gammaherpesviruses depends critically on the expansion of viral genomes in germinal centre (GC) B cells. Yet, host and virus molecular mechanisms involved in driving such proliferation remain largely unknown. Here, we show that the ORF73 protein encoded by the murid herpesvirus-4 (MuHV-4) inhibits host nuclear factor-kappa B (NF-jB) transcriptional activity through poly-ubiquitination and subsequent proteasomal-dependent nuclear degradation of the NF-jB family member p65/RelA. The mechanism involves the assembly of an ElonginC/Cullin5/SOCS (suppressors of cytokine signalling)-like complex, mediated by an unconventional viral SOCS-box motif present in ORF73. Functional deletion of this SOCS-box motif ablated NF-jB inhibitory effect of ORF73, suppressed MuHV-4 expansion in GC B cells and prevented MuHV-4 persistent infection in mice. These findings demonstrate that viral inhibition of NF-jB activity in latently infected GC centroblasts is critical for the establishment of a gammaherpesvirus persistent infection, underscoring the physiological importance of proteasomal degradation of RelA/NF-jB as a regulatory mechanism of this signalling pathway.

Research paper thumbnail of Complex Alternative Cytoplasmic Protein Isoforms of the Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen 1 Generated through Noncanonical Translation Initiation

Journal of Virology, 2012

Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) p... more Kaposi's sarcoma-associated herpesvirus (KSHV) latency associated-nuclear antigen 1 (LANA1) protein is constitutively expressed in all KSHV-infected cells, as well as in all forms of KSHV-associated malignancies. LANA1 is a multifunctional KSHV oncoprotein containing multiple repeat sequences that is important for viral episome maintenance and the regulation of cellular and viral gene expression. We characterize here multiple LANA1 isoforms and show that ∼50% of LANA1 is naturally generated as N-terminally truncated shoulder proteins that are detected on SDS-PAGE as faster-migrating shoulder bands designated LANA1 S . Higher-molecular-weight LANA1 S isoforms initiate downstream at noncanonical sites within the N-terminal region, whereas lower-molecular-weight LANA1 S isoforms initiate downstream within the central repeat 1 domain. LANA1 S proteins lack an N-terminal nuclear localization signal motif, and some isoforms differ from full-length, canonical LANA1 by localizing to per...

Research paper thumbnail of Lentiviral target-specific strategy for molecular therapy

Tese de doutoramento, Farmacia (Microbiologia), Universidade de Lisboa, Faculdade de Farmacia, 2012

Research paper thumbnail of KSHV Latency in Transformed B-cells: The Role of LANA1 as a Therapeutic Target

Virology: Research and Treatment

Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kapo... more Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kaposi as an idiopathic, multiple pigmented sarcoma of the skin. This type of KS, later classifi ed as classic KS, predominantly occurred in elderly people, particularly men of Mediterranean, Eastern European, or Jewish descent. A high occurrence of African or endemic KS was reported during the early 1950's in equatorial African countries, while during the 1960's KS emerged among immune-suppressed patients following organ transplantation. A tremendous increase in the incidence of KS was noticed during the early 1980's in parallel with the acquired immunodefi ciency syndrome (AIDS) epidemic, leading to a formal recognition of KS as an AIDS-associated malignancy. The geographic variations in the incidence of KS together with the relatively high occurrence of AIDS-KS, particularly among homosexual men, suggested the existence of a unique KS infectious agent (7, 8). In 1994 Chang and colleagues, amplifi ed two novel DNA sequences from an AIDS-associated KS lesion, by using a subtractive hybridization technique (representational difference analysis (RDA)). These sequences displayed homology to herpesviral capsid and tegument genes and led to the complete sequencing of the 165 Kbp viral genome of the newly discovered virus, Kaposi's Sarcoma-Associated Herpesvirus (KSHV) or human herpesvirus 8 (HHV-8). KSHV was established as being present in virtually all pathologically confi rmed KS specimens (11, 12). Treatment with highly active antiretroviral therapy (HAART) has been associated with a dramatic decline in the incidence of KS (31), so that AIDS-associated KS is uncommon overall in the Western world. Sub-Saharan Africa has the highest rates of infection (due mostly to the high rates of AIDS) with many countries experiencing sera-prevalence rates exceeding 60%, so that in certain African countries it is now the most common cancer in adult men, and the second most common in adult women (44). The incidence of KS among transplant recipients is proportional to the ethno-geographical prevalence of KSHV, ranging from 0.5% in most Western countries to 5.3% in Saudi Arabia (50). In addition to KS, which is a tumour of endothelial cell origin, several haematological predominantly B cell disorders are also associated with KSHV. The two most well characterized are AIDS-associated primary effusion lymphomas (PEL) and a subset of multicentric Castleman's disease (MCD), an aggressive lymphoproliferative disorder. PELs are monoclonal, non-Hodgkin's B cell lymphomas that are commonly co-infected with EBV. Cell lines established from PEL, unlike KS tumour explants, stably maintain viral episomes at high copy number (30-150 copies per cell) and are the source of virus for most virologic and serologic studies. Most studies on latency of gammaherpesviruses (EBV) used lymphoblastoid cell lines that were derived from lymphomas or were established by in vitro infection/immortalization of peripheral blood lymphocytes. In vitro immortalized cells lines can be cultured indefi nitely. PEL cell lines that carry latent KSHV have been successfully established, although no in vitro immortalization of B lymphocytes has been reported yet (10, 44). KSHV viral genome consists of a ∼140kb long unique coding region fl anked by a multiple GC rich ∼800bp TRs (terminal repeats) giving a total estimated size of around 170kb (57, 60). In analogy

Research paper thumbnail of KSHV Latency in Transformed B-cells: The Role of LANA1 as a Therapeutic Target

Virology: Research and …, 2008

Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kapo... more Kaposi's sarcoma (KS) was originally described in 1872 by the Hungarian dermatologist Moritz Kaposi as an idiopathic, multiple pigmented sarcoma of the skin. This type of KS, later classifi ed as classic KS, predominantly occurred in elderly people, particularly men of Mediterranean, Eastern European, or Jewish descent. A high occurrence of African or endemic KS was reported during the early 1950's in equatorial African countries, while during the 1960's KS emerged among immune-suppressed patients following organ transplantation. A tremendous increase in the incidence of KS was noticed during the early 1980's in parallel with the acquired immunodefi ciency syndrome (AIDS) epidemic, leading to a formal recognition of KS as an AIDS-associated malignancy. The geographic variations in the incidence of KS together with the relatively high occurrence of AIDS-KS, particularly among homosexual men, suggested the existence of a unique KS infectious agent (7, 8). In 1994 Chang and colleagues, amplifi ed two novel DNA sequences from an AIDS-associated KS lesion, by using a subtractive hybridization technique (representational difference analysis (RDA)). These sequences displayed homology to herpesviral capsid and tegument genes and led to the complete sequencing of the 165 Kbp viral genome of the newly discovered virus, Kaposi's Sarcoma-Associated Herpesvirus (KSHV) or human herpesvirus 8 (HHV-8). KSHV was established as being present in virtually all pathologically confi rmed KS specimens (11, 12). Treatment with highly active antiretroviral therapy (HAART) has been associated with a dramatic decline in the incidence of KS (31), so that AIDS-associated KS is uncommon overall in the Western world. Sub-Saharan Africa has the highest rates of infection (due mostly to the high rates of AIDS) with many countries experiencing sera-prevalence rates exceeding 60%, so that in certain African countries it is now the most common cancer in adult men, and the second most common in adult women (44). The incidence of KS among transplant recipients is proportional to the ethno-geographical prevalence of KSHV, ranging from 0.5% in most Western countries to 5.3% in Saudi Arabia (50). In addition to KS, which is a tumour of endothelial cell origin, several haematological predominantly B cell disorders are also associated with KSHV. The two most well characterized are AIDS-associated primary effusion lymphomas (PEL) and a subset of multicentric Castleman's disease (MCD), an aggressive lymphoproliferative disorder. PELs are monoclonal, non-Hodgkin's B cell lymphomas that are commonly co-infected with EBV. Cell lines established from PEL, unlike KS tumour explants, stably maintain viral episomes at high copy number (30-150 copies per cell) and are the source of virus for most virologic and serologic studies. Most studies on latency of gammaherpesviruses (EBV) used lymphoblastoid cell lines that were derived from lymphomas or were established by in vitro infection/immortalization of peripheral blood lymphocytes. In vitro immortalized cells lines can be cultured indefi nitely. PEL cell lines that carry latent KSHV have been successfully established, although no in vitro immortalization of B lymphocytes has been reported yet (10, 44). KSHV viral genome consists of a ∼140kb long unique coding region fl anked by a multiple GC rich ∼800bp TRs (terminal repeats) giving a total estimated size of around 170kb (57, 60). In analogy

Research paper thumbnail of Termination of NF-κB activity through a gammaherpesvirus protein that assembles an EC5S ubiquitin-ligase

The EMBO Journal, 2009

Host colonisation by lymphotropic gammaherpesviruses depends critically on the expansion of viral... more Host colonisation by lymphotropic gammaherpesviruses depends critically on the expansion of viral genomes in germinal centre (GC) B cells. Yet, host and virus molecular mechanisms involved in driving such proliferation remain largely unknown. Here, we show that the ORF73 protein encoded by the murid herpesvirus-4 (MuHV-4) inhibits host nuclear factor-kappa B (NF-jB) transcriptional activity through poly-ubiquitination and subsequent proteasomal-dependent nuclear degradation of the NF-jB family member p65/RelA. The mechanism involves the assembly of an ElonginC/Cullin5/SOCS (suppressors of cytokine signalling)-like complex, mediated by an unconventional viral SOCS-box motif present in ORF73. Functional deletion of this SOCS-box motif ablated NF-jB inhibitory effect of ORF73, suppressed MuHV-4 expansion in GC B cells and prevented MuHV-4 persistent infection in mice. These findings demonstrate that viral inhibition of NF-jB activity in latently infected GC centroblasts is critical for the establishment of a gammaherpesvirus persistent infection, underscoring the physiological importance of proteasomal degradation of RelA/NF-jB as a regulatory mechanism of this signalling pathway.